{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following Patents and Patent Applications to Etubics Corporation (\"Etubics\") located in San Francisco, California, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/05/19/2016-11770.html","cfr_references":[],"citation":"81 FR 31650","comment_url":null,"comments_close_on":"2016-06-03","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 3, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-11770","effective_on":null,"end_page":31651,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/05/19/2016-11770.xml","html_url":"https://www.federalregister.gov/documents/2016/05/19/2016-11770/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-adeno-virus-based","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-11770?publication_date=2016-05-19","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-05-19/2016-11770/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":151,"last_updated":"2026-07-26 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-05-19/pdf/2016-11770.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-11770.pdf?1463575557","publication_date":"2016-05-19","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/05/19/2016-11770.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:43:42Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":31650,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy","toc_doc":"Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy","toc_subject":"Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":81}